Clinical Trials Directory

Trials / Completed

CompletedNCT00893841

Bipolar Study of Seroquel XR With Pramipexole Dihydrochloride

A Randomized, Double-Blind, Placebo Controlled Exploratory Study of Augmentation of Seroquel XR With Pramipexole Dihydrochloride for Bipolar Depression

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
96 (actual)
Sponsor
Dr. D McIntosh & Dr. K Kjernisted Clinical Research Inc. · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

This study is designed to assess the use of pramipexole dihydrochloride and quetiapine (Seroquel) XR as combination therapy for bipolar depression. The proposed benefit of the combination therapy investigated in this study is improved treatment of bipolar depression.

Detailed description

Quetiapine is a first-line option in Canadian guidelines for the treatment of bipolar depression; however, there is room for improvement as the remission rate is approximately 50% and the response rate is approximately 60%. Pramipexole, which is currently used to treat Parkinson's disease and restless legs syndrome, is reported to have antidepressant effects in patients with unipolar or bipolar depression. There are no other clinical studies to evaluate the efficacy of pramipexole combined with an atypical antipsychotic, such as quetiapine XR, in the treatment of bipolar depression. This study is a multicentre, randomized, double-blind and placebo-controlled exploratory study in which patients will receive one of three treatment arms for a treatment period of 16 weeks: quetiapine XR plus placebo, quetiapine XR plus 0.25mg pramipexole, or quetiapine XR plus 0.50mg pramipexole.

Conditions

Interventions

TypeNameDescription
DRUGquetiapine (Seroquel) XRtablets and caplets, take with liquid before bedtime
DRUGquetiapine (Seroquel) XRtablets, take with liquid before bedtime
DRUGplaceboplacebo
DRUGpramipexole dihydrochloridetablets and caplets, take with liquid before bedtime

Timeline

Start date
2009-02-01
Primary completion
2013-01-01
Completion
2013-01-01
First posted
2009-05-06
Last updated
2013-02-04

Locations

9 sites across 2 countries: United States, Canada

Source: ClinicalTrials.gov record NCT00893841. Inclusion in this directory is not an endorsement.